Gary Lee
Chief Tech/Sci/R&D Officer at LYELL IMMUNOPHARMA, INC.
Net worth: 27 940 $ as of 2024-04-29
Profile
Gary Lee is currently the Chief Scientific Officer at Lyell Immunopharma, Inc. He previously held the position of Vice President-Cell Therapy at Sangamo Therapeutics, Inc. from 2005 to 2018.
From 2018 to 2022, he served as the Chief Scientific Officer at Senti Sub I, Inc. Dr. Lee completed his undergraduate degree at the California Institute of Technology and obtained a doctorate degree from the University of California, Berkeley.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
LYELL IMMUNOPHARMA, INC.
0.00% | 2024-03-30 | 12,700 ( 0.00% ) | 27 940 $ | 2024-04-29 |
Gary Lee active positions
| Companies | Position | Start |
|---|---|---|
| LYELL IMMUNOPHARMA, INC. | Chief Tech/Sci/R&D Officer | 2022-01-30 |
Former positions of Gary Lee
| Companies | Position | End |
|---|---|---|
Senti Sub I, Inc.
 Senti Sub I, Inc. BiotechnologyHealth Technology Senti Biosciences, Inc. develops novel therapeutics. It specializes in thetic biology, gene therapy and cell therapy. The company was founded by Timothy K. Lu, Wilson Wong, James J. Collins and Philip Lee in 2016 and is headquartered in South San Francisco, CA. | Chief Tech/Sci/R&D Officer | 2021-12-31 |
| SANGAMO THERAPEUTICS, INC. | Corporate Officer/Principal | 2018-09-30 |
Training of Gary Lee
| University of California, Berkeley | Doctorate Degree |
| California Institute of Technology | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| SANGAMO THERAPEUTICS, INC. | Health Technology |
| LYELL IMMUNOPHARMA, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Senti Sub I, Inc.
Senti Sub I, Inc. BiotechnologyHealth Technology Senti Biosciences, Inc. develops novel therapeutics. It specializes in thetic biology, gene therapy and cell therapy. The company was founded by Timothy K. Lu, Wilson Wong, James J. Collins and Philip Lee in 2016 and is headquartered in South San Francisco, CA. | Health Technology |
- Stock Market
- Insiders
- Gary Lee
